High C‐reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol

References

• Manson J. E., Hsia J., Johnson K. C., Rossouw J. E., Assaf A. R., Lasser N. L., et al. and the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–34
   PubMed Web of Science ®Google Scholar
• Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13
   PubMed Web of Science ®Google Scholar
• Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow‐up (HERS‐II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Whaley‐Connell A., Palmer J., Sowers J. R. Can drospirenone with 17‐β estradiol safely reduce blood pressure in hypertensive postmenopausal women? [commentary]. Nature Clin Pract Endocrinol Metab 2005; 1: 72–3
   PubMedGoogle Scholar
• Humphrey L. L., Chan B. K., Sox H. C. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Inter Med 2002; 137: 273–84
   PubMed Web of Science ®Google Scholar
• Mosca L., Collins P., Herrington D. M., Mandelsohn M. E., Pasternak A. C., Robertson R. C., et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499–503
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Hennikens C. H., Buring J. E., Rifai N. C‐reactive protein and other markers of inflammation in the predictor of cardiovascular disease in women. New Engl J Med 2000; 342: 836–43
   PubMed Web of Science ®Google Scholar
• Pearson T. A., Mensah G. A., Alexander R. W. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Buring J. E., Cook N. R., Rifai N. C‐reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8‐year follow‐up of 14,719 initially healthy American women. Circulation 2003; 107: 391–7
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Hennekens C. H., Rifai N., Buring J. E., Manson J. E. Hormone replacement therapy and increased plasma concentration of C‐reactive protein. Circulation 1999; 100: 713
   PubMed Web of Science ®Google Scholar
• Cushman M., Legault C., Barrett‐Connor E., Stefanick M. L., Kessler C., Judd H. L., et al. Effect of postmenopausal hormones on inflammation‐sensitive proteins: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Circulation 1999; 100: 717–22
   PubMed Web of Science ®Google Scholar
• Post M. S., van der Mooren M. J., Stehouwer C. D., Van Baal W. M., Mijatonic V., Schalkuijk C. G., et al. Effect of transdermal and oral oestrogen replacement therapy on C‐reactive protein levels in postmenopausal women: a randomised, placebo‐controlled trial. Thromb Haemost 2002; 88: 605–10
   PubMed Web of Science ®Google Scholar
• Wanpen V., Meryem T., Zhongyun W., Debbie A., Borna M., Ishwarlal J. Differential effects of oral versus transdermal estrogen replacement therapy on C‐reactive protein in postmenopausal women. J Am Coll Cardiol 2003; 41: 1358–63
   PubMed Web of Science ®Google Scholar
• Strandberg T. E., Ylikorkala O., Tikkanen M. J. Differing effect of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy women. Am J Cardiol 2003; 92: 212–4
   PubMed Web of Science ®Google Scholar
• Decensi A., Omodei U., Robertson C., Bonnani B., Guerrierri‐Gonzaga A., Ramazzotto F., et al. Effect of transdermal estradiol and oral conjugated estrogen on C‐reactive protein in a retinoid‐placebo trial in healthy women. Circulation 2002; 106: 1224–8
   PubMed Web of Science ®Google Scholar
• Stojanovic N. D., Kwong P., Byrne D. J., Arnold A., Jagroop I. A., Nair D., et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 2003; 54: 391–9
   PubMed Web of Science ®Google Scholar
• Varila E., Wahlstrom T., Rauramo I. A 5‐year follow‐up study on the use of a levonorgestel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76: 969–73
   PubMed Web of Science ®Google Scholar
• Baudner S., Dati F. Protein in human‐serum auf der basis des neuen IFCC/BCR/CAP Internationalen Referenzmaterials CRM 470. J Lab Med 1996; 20: 145–52
   Google Scholar
• Suleiman M., Aronson D., Reisner S. A., Kapeliovich M. R., Markiewicz W., Levy Y., et al. Admission C‐reactive protein levels and 30‐day mortality in patients with acute myocardial infarction. Am J Med 2003; 115: 695–701
   PubMed Web of Science ®Google Scholar
• Boulman N., Levy Y., Leiba R., Shachar S., Linn R., Zinder O., et al. Increased C‐reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160–5
   PubMed Web of Science ®Google Scholar
• Simon J. A., Hsia J., Cauley J. A., Richards C., Harris F., Fong J., et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation 2001; 103: 638–42
   PubMed Web of Science ®Google Scholar
• Luukkainen T. Issues to debate on the Women's Health Initiative Study. Failure of estrogen plus progestin therapy for prevention of breast cancer risk. Hum Reprod 2003; 18: 1559–63
   PubMed Web of Science ®Google Scholar
• Hays J., Ockene J. K., Brunner R. L., Kotchen J. M., Manson J. E., Patterson R. E., et al. and the Women's Health Initiative Investigators. Effect of estrogen plus progestin on health‐related quality of life. N Engl J Med 2003; 348: 1839–54
   PubMed Web of Science ®Google Scholar
• Luyer M. D. P., Khosla S., Owen W. G., Miller V. M. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrin Metab 2001; 86: 3629–34
   PubMed Web of Science ®Google Scholar
• Aronson D., Bartha P., Zinder O., Kerner A., Shitman E., Brook J. G., et al. Association between fasting glucose and C‐reactive protein in middle‐aged subjects. Diabet Med 2004; 21: 39–44
   PubMed Web of Science ®Google Scholar
• Aronson D., Bartha P., Zinder O., Markiewicz W., Avizohar O., Brook J. G., et al. Obesity is the major determinant of elevated C‐reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004; 28: 674–9
   PubMed Web of Science ®Google Scholar
• Skouby S. O., Gram J., Andersen L. F., Sidelmann J., Petersen K. R., Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C‐reactive protein concentrations. Am J Obstet Gynecol 2002; 186: 969–77
   PubMed Web of Science ®Google Scholar
• Warming L., Ravn P., Christiansen C. Levonorgestrel and 17beta‐estradiol given transdermally for the prevention of postmenopausal osteoporosis. Maturitas 2005; 14;50: 78–85
   Web of Science ®Google Scholar
• Hampton N. R., Rees M. C., Lowe D. G., Rauramo I., Barlow D., Guillebaud J. Levonorgestrel intrauterine system (LNG‐IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005; 20: 2653–60
   PubMed Web of Science ®Google Scholar